PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.64%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-14.64%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-15.16%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
2.78%
Positive EPS growth while TRVN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
2.78%
Positive diluted EPS growth while TRVN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
19.07%
Share count expansion well above TRVN's 9.48%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
19.07%
Diluted share count expanding well above TRVN's 9.48%. Michael Burry would fear significant dilution to existing owners' stakes.
-16.01%
Dividend reduction while TRVN stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-25.31%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-30.01%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2395.20%
Negative 10Y OCF/share CAGR while TRVN stands at 81.33%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
87.33%
5Y OCF/share CAGR is similar to TRVN's 80.66%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
68.32%
3Y OCF/share CAGR at 75-90% of TRVN's 76.18%. Bill Ackman would press for improvements in margin or overhead to catch up.
-1414.90%
Negative 10Y net income/share CAGR while TRVN is at 66.80%. Joel Greenblatt sees a major red flag in long-term profit erosion.
92.17%
5Y net income/share CAGR 1.25-1.5x TRVN's 75.34%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
80.18%
3Y net income/share CAGR 1.25-1.5x TRVN's 68.19%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
1411.37%
Below 50% of TRVN's 23230.91%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
-77.60%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-28.05%
Negative 3Y equity/share growth while TRVN is at 18.51%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.41%
Asset growth above 1.5x TRVN's 4.22%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
13.37%
Positive BV/share change while TRVN is negative. John Neff sees a clear edge over a competitor losing equity.
-15.85%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
22.47%
We increase R&D while TRVN cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-1.59%
We cut SG&A while TRVN invests at 101.20%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.